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Abstract 
In this extensive review, we elucidate the importance of proteases and their role in drug 
development in various diseases with an emphasis on cancer. First, key proteases are in-
troduced along with their function in disease progression. Next, we link these proteases as 
targets for the development of prodrugs and provide clinical examples of protease-activatable 
prodrugs. Finally, we provide significant design considerations needed for the development of 
the next generation protease-targeted and protease-activatable prodrugs. 
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1. Introduction 
Proteases play a fundamental and essential role 
in many biological and pathological processes by the 
regulatory mechanism, proteolysis. Proteolysis is an 
irreversible regulatory mechanism and now known to 
selectively  cleave  specific  substrates.  Additionally, 
multimeric  and  multicatalytic  proteases  exist  to  de-
grade  multiple  intracellular  proteins,  called  pro-
teasomes,  essential  for  biological  processes  [1].  The 
human degradome, which makes up a complete list of 
proteases synthesized by human cells, is made up of 
at  least  569  proteases  that  are  distributed  into  five 
broad classes (in order from greatest to least number): 
metalloproteinases,  serine,  cysteine,  threonine,  and 
aspartic proteases [2]. Serine, cysteine and threonine 
proteases are involved in covalent catalysis. The nu-
cleophile of the catalytic site is part of the specified 
amino acid. Metalloproteinases and aspartic proteases 
perform non-covalent catalysis and the nucleophile is 
an activated water molecule [3]. 
By their highly controlled actions, proteases play 
influential roles in DNA replication and transcription, 
cell  proliferation  and  differentiation,  angiogenesis, 
neurogenesis,  ovulation,  fertilization,  wound  repair, 
stem cell mobilization, hemostasis, blood coagulation, 
inflammation,  immunity,  senescence,  necrosis  and 
apoptosis [4]. Therefore, deregulated modifications in 
proteolytic actions underlie many diseases like cancer 
and neurodegenerative and cardiovascular disorders. 
Because of proteases’ ability to degrade extracellular 
matrices  and  proteins,  they  are  strongly  associated 
with  cancer  progression,  specifically  invasion  and 
metastasis. Additionally, intracellular proteases, like 
lysosomal  cysteine  proteases,  are  involved  in  more 
protective  mechanisms,  like  degrading  many  endo-
cytosed proteins and foreign bodies.  
With strong evidence of protease involvement in 
diseases,  proteases  serve  an  important  role  in  drug 
development. Some therapies have been formulated 
to target and inhibit proteases and proteasomes that 
are  dysregulated,  especially  for  tumor  suppression. 
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Proteasome  inhibitors  have  shown  success  in  treat-
ment  of  haematological  malignancies  and  have 
therefore  been  tested  as  therapeutic  agents  in  the 
clinic for over 10 years [5]. The first inhibitor, borte-
zomib has been used as a treatment for relapsed mul-
tiple myeloma and mantle cell lymphoma. However, 
the  use  of  such  expansive  protease  inhibitors  have 
shown a lack of success overall. For a comprehensive 
review of clinical successes and failures of protease 
inhibitors see reference [3] and of proteasome inhibi-
tors see reference [5]. Therefore, more specific prote-
ase-inspired therapies have been attempted. First, the 
design of recombinant forms of proteases can replace 
defective protease but are limited by the large doses 
necessary to achieve this effect. Second, gene-therapy 
approaches targeting protease genes can intrinsically 
improve proper protease activity. This approach has 
been show to work in lentiviral-mediated neprilysin 
gene  transfer  to  block  prostate  cancer  growth  [6]. 
Third,  an  indirect  approach  is  to  hamper  protease 
inhibitors to reduce protective (anti-tumor) proteases. 
In this way, proteases are activated that can sensitize 
cancer cells to drug treatments or induce apoptosis, as 
seen by Karikari, et al. for the inhibition of caspase 
inhibitors to induce apoptosis in pancreatic cancer [7]. 
Fourth, proteases can serve as biomarkers for diagno-
sis or prognosis of tumors. The presence of protective 
proteases can predict good clinical prognosis but their 
absence can indicate the need for different treatments. 
Dysregulated  proteolytic  activities  can  signify  the 
progression  of  disease.  An  effective  detection  tech-
nique is the use of protease activatable probes [8-11]. 
Activatable probes, or molecular beacons, can signal, 
typically by fluorescence, the detection of proteases 
after the protease degrades the linkage between the 
dye and a quencher.  In other words, the probe in its 
natural form gives off no signal; but only once a spe-
cific protease is present and degrades its specific sub-
strate,  the  probe  is  activated.  Using  a  similar  ap-
proach,  protease-activated  prodrugs  (PAPs)  can  be 
exploited  to  improve  drug  delivery  to  areas  where 
protease  expression,  like  in  malignant  tissues,  is 
higher than in normal tissues.  
Prodrugs are derivatives of drug molecules that 
can undergo a transformation by an enzyme, chemical 
or environmental stimuli to release the active parent 
drug in vivo [12]. Just as activatable probes, prodrugs 
in their native state are inactive forms of the drug but 
only after a stimuli release an active drug. In this way, 
prodrugs are an extremely efficient approach to in-
crease  selectivity  and  efficacy  of  chemotherapy,  re-
ducing the toxic effects on healthy cells. By chemical 
conjugation,  prodrugs  improve  all  pharmaceutical 
properties of the parent drug, such as its solubility, 
stability, permeability and distribution [12-13]. Since 
prodrugs  can  overcome  major  hurdles  of  drug  for-
mulations  like  poor  solubility  or  instability,  previ-
ously  unsuitable  drugs  for  clinical  use  can  now  be 
utilized.  It  has  been  estimated  that  about  5-7%  of 
drugs currently approved worldwide are classified as 
prodrugs and that an even larger amount of prodrugs 
are approved every year [14]. Prodrugs are made up 
of the parent drug conjugated with a promoiety, like a 
polymer or peptide substrate via a cleavable linkage 
and/or a targeting moiety for specific delivery like an 
antibody  or  aptamer.  Common  functional  groups 
used  to  modify  prodrugs  for  superior  properties, 
called promoieties, are listed in ref.  [12]. In this re-
view, we will focus on enzyme cleavable prodrugs, 
specifically  protease-cleavable.    Using  this  strategy, 
the prodrug only achieves its active form when the 
enzyme  of  interest,  for  which  the  promoiety  is  its 
substrate, cleaves it. Therefore, the drug is released at 
a specific location where the enzyme is overexpressed. 
This review will focus on the promising devel-
opment  of  PAPs.  We  will  introduce  the  key  target 
proteases and their involvement in specific diseases 
and  further  discuss  the  development  of  preclinical 
and clinical prodrugs utilizing these proteases. Final-
ly, we will give a perspective on design considerations 
to develop advanced, efficient PAPs. The review will 
give the reader a background on the important pro-
teases  involved  in  various  diseases,  the  design  and 
outcomes of prodrugs used to target and treat these 
diseases and an outlook of how this field can advance 
further. 
2. Target proteases 
Aberrant  protease  signaling  pathways  lead  to 
cancer as well as neurodegenerative, cardiovascular 
and pulmonary diseases.  Specific substrates for up-
regulated proteases can be used as a  promoiety for 
prodrugs, where the substrate is catalyzed to activate 
the  prodrug  into  therapeutics.  Currently,  a  large 
number  of  proteases  have  been  identified  as  bi-
omarkers for early diagnostic and prognostic markers, 
especially  for  cancer.  Here  we  will  discuss  which 
proteases  are  particularly  identified  in  pathological 
disorders and their substrates (Table 1 and 2). A pro-
tease substrate contains a recognition sequence for the 
protease to cleave. But in order to be used in prodrug 
design, the substrate must reach the same location as 
the protease [3].  
In  terms  of  cancer,  dysregulated  intracellular 
proteases can cause a loss of protective mechanisms 
and cause overgrowth and overexpression  of extra-
cellular proteases, which has been shown to result in 




kinase plasminogen activator (uPA), cathepsin B, and 
membrane-type matrix metalloproteinase (MMP) can 
initiate the activation of pro-MMPs. Then, extracellu-
lar matrix (ECM) degrading activities begin by extra-
cellular  serine  proteases,  like  uPA,  urokinase  plas-
minogen activator receptor (uPAR), plasminogen, and 
MMPs to initiate cellular motility, invasiveness and a 
further cascade of tumor growth factors [15-17]. Re-
cently,  work  has  shown  that  certain  extracellular 
proteases  have  anti-tumor  properties  [2].  Yet,  over-
expressed proteases have been identified in cancerous 
cells  numerous  concentration  folds  higher  than  in 
healthy cells [16]. Therefore the development of PAPs 
allows for specific, active drug delivery to cancer sites. 
Proteases are produced not only by tumor cells but 
also by multiple cell types recruited to the tumor site 
[18]. Therefore, the protease substrate selected in the 
prodrug can be catalyzed directly in the tumor mi-
croenvironment  to  reduce  non-specific  toxicity  in 
normal  proliferating  and  healthy  cells.  Here  we  in-
troduce key proteases linked in cancer progression – 
cathepsins, kallikreins, uPA, uPAR, caspase and ma-
trix  metalloproteinases.  Then  we  summarize  their 
roles in other diseases. 
 
Table 1. Target proteases and diseases associated with overexpressed proteases 
 
*Abbreviations: AD: Alzheimer’s disease; ADAM: a disintegrin and metalloproteinase domain protease; COPD: chronic obstructive pulmonary disease; ER: 
endoplasmic reticulum; RA: rheumatoid arthritis 
 
 
Family  Protease  Location  Cancer  Ref.  Other Diseases  Ref. 
Cysteine 
Cathepsins 
General  Intracellular, 
lysosomes  Most  Table in 
[121]     
Cathepsin K  Extracellular, 
bone  Breast  [178]  Artherosclerosis, 








Breast,  cervix, colon,  
colorectal, gastric, head and 
neck, liver, lung,  melanoma, 
ovarian,  pancreatic, prostate, 
thyroid 
[31, 38, 81, 
183-196]     







Cervical, gastric, lung, 
pancreas adenocarcinomas  [51-55]     
Cathepsin D  Lysosome  Breast, colorectal, ovarian  [47-49, 198-
200]  Atherosclerosis   [121] 
Kallikreins 
(hK) 
General  Intracellular, 
secreted  Most  Table in [15, 
58]     
hK1        Hypertension, 
inflammation  [24] 
PSA (hK 3)    Prostate, ovarian  [201-202]     
hK10    Colon, ovarian, pancreatic, 
head and neck  [203-206]     
hK15    Ovarian, prostate  [207-208]     
Serine 
Proteases  uPA, uPAR  Membrane, 
Pericellular 
Cervical, colorectal, gastric, 
prostate 
[86, 116, 
209-210]     
Caspases    Intracellular      Neurodegenerative 
disorders  [82] 
MMPs 
General  Extracellular  Most  Table in 
[211]     
MMP-1, -8, -13    Breast  [85, 102-104, 
211-212]  Artherosclerosis, RA  [213-214] 
MMP-2, -9    Breast, colorectal, lung, 




asthma, COPD, cystic 
fibrosis, HIV 
associated dementia, 
hypertension, stroke  
[87, 113-
117] 
MMP-14  Membrane  Breast  [212]     
ADAM    Extracellular      AD  [105, 107, 
112] 




Table 2. Protease-activatable prodrugs 
 
* Abbreviations : 4-AB: 4-aminobenzyl alcohol, ALB: albumin, ALN: alendronate, ara-C: 1-8-D-arabinofuranosylcytosine, AT-125: 
α-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, BHQ3: black hole quencher 3, cAC10: chimeric anti-CD30 monoclonal antibody, CAR: carotenoid, Ce6: 
chlorine e6, c1F6: chimeric anti-CD70 monoclonal antibody, chGly: cyclohexaglycyl, Cit: citrulline, CPT: camptothecin, CP: carboxypeptidase, dAc: desacetyl, 
DEX: dextran, DNR: daunorubicin, DOX: doxorubicin, DTX: docetaxel, EMC: ε-maleimidocaproic acid, FAP: fibroblast activation protein, 5-FU: 5-fluorouracil, 
5-FudR: 5-fluorodeoxyuridine, GAL: galactose, Hof: homophenylalanine, HPMAcp: N-(2-hydroxypropyl)methacrylamide copolymer, Hyp: 
trans-4-hydroxyproline, L12ADT: 8-O-(12[L-leucinoylamino]dodecanoyl)-8-O-debutanoylthapsigargin, MTX: metotrexate, MMAE: monomethyl auristatin E, 
MMP: matrix metalloproteinase, Mu: morpholinocarbonyl, Nle: norleucyl, PABC: para aminobenzyloxycarboxyl, PEG: polyethylene glycol, Pep42: a cyclic 
13-mer oligopeptide, PH-A: pheophorabide a, Pip: piperidine, PM: N,N-bis(2-chloroethyl)-p-phenylenediamine (phenylenediamine mustard), PSA: pros-
tate-specific antigen, PTX: paclitaxel, PtD: platinum-based drug, PGE1: prostaglandin E1, RA: rheumatoid arthritis, RGD-4C: bicyclic 
Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys, SN-392: 10-amino-7-hydroxy camptothecin, TNP-470: O-(chloracetyl-carbamoyl) fumagillol, TOP: thimet oligopepti-
dase, TPG: thapsigargin, VNB: vinblastine, X: therapeutic agent or its analogue 
Protease  Construct  Drug  Disease  Ref. 
Peptide-based prodrug 
Caspase-3  Asp-Glu-Val-Asp-Pro-PABC-X 
CAR-Lys-Gly-Ser-Gly-Asp-Val-Glu-Gly-X  DOX, PH-A  Cancer  [215-217] 
Cathepsin B  N-L-Leu-X  DNR, DOX  Cancer, 
RA  [124-130] 
CP  Arg-X, Ala-X, Asp-X  MTX  Cancer  [218] 
FAP  BHQ3-Lys-Gln-Glu-Gln-Asn-Pro-Gly-Ser-Thr-X  PH-A  Cancer  [219] 
Kallikrein 2  Gly-Lys-Ala-Phe-Arg-Arg-X  TPG  Cancer  [220, 221] 
MMP-2/-9/-14  Glu-Pro-Cit-Gly-Hof-Tyr-Leu-X  DOX  Cancer  [157, 158] 
MMP-7  BHQ3-Lys-Arg-Ala-Leu-Gly-Leu-Pro-Gly-X 


















Cancer  [148-153, 
231-234] 
TOP  β-Ala-L-Leu-L-Ala-L-Leu-X  DOX  Cancer  [235-239] 

















Cathepsin K  HPMAcp-Gly-Gly-Pro-Nle-4AB-X  ALN, PGE1  Bone 
disease  [243-245] 
MMP-2/-9  DEX-Gly-Ile-Leu-Gly-Val-Pro-X 
ALB-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln-X  DOX, MTX  Cancer  [159-161, 
246] 
Plasmin  ALB-EMC-D-Ala-Phe-Lys-Lys-X  DOX  Cancer, 
RA  [242, 247] 
PSA  ALB-EMC-Arg-Arg-Ser-Ser-Tyr-Tyr-Ser-Gly-X 
HPMAcp-morpholinocarbonyl-Ser-Ser-Lys-Tyr-Gln-Leu-X  DOX, TPG  Cancer  [154-156] 
Thrombin  PEG-poly-L-lysine-X 
poly-L-lysin-Gly-D-Phe-Pip-Arg-Ser-Gly-Gly-Gly-Gly-Gly-X  Ce6, PH-A  Cancer, 
RA  [248-250] 
Trypsin  poly-L-lysine-X 
poly-L-lysine-Gly-Ala-Ser-D-Arg-Phe-Thr-Gly-X  PH-A  Cancer  [251, 252] 








PTX  Cancer  [164, 175, 
254-257] 
Plasmin  RGD-4C-D-Ala-Phe-Lys-(PABC)n-X  MTX  Cancer, 
RA  [172] 




2.1. Cathepsins  
Cysteine  cathepsins  are  primarily  intracellular, 
lysosomal proteases that are responsible for protein 
turnover but have shown to be upregulated in cancer, 
often in early lesions  [19]. Cathepsin-catalyzed sub-
strate cleavage usually involves nucleophilic cysteine 
thiol, histidine, and an aspartate in the active site and 
cleavage is favored by acidic conditions [16]. Howev-
er, specific substrates of cysteine cathepsins involved 
in pathological conditions need to be determined [19]. 
Overexpressed cysteine cathepsins are implicated in 
glioma [20-21], melanoma [22], cancer of the esopha-
gus[23],  stomach  [24],  colon  [25],  prostate  [26-27], 
breast  [28]  and  lung  [29]  and  have  been  used  as 
pathological biomarkers [30]. Active cysteine cathep-
sins are  most commonly found in the acidic condi-
tions of lysosomes with some exceptions. Cathepsin K 
is  normally  excreted  to  the  extracellular  space  be-
tween  osteoclasts  and  bone  for  bone  remodeling 
[31-32].  Although  intracellular  proteases  are  less 
studied in their role in cancer compared to the more 
common  ECM-degrading  proteases  like  MMP  and 
uPA, deregulation in their locations can initiate fur-
ther  extracellular  proteolytic  cascades  [33-34].  For 
example, secreted cathepsin B and L hydrolyze type 
IV  collagen,  fibronectin  [35],  cell-adhesion  proteins 
[36] and laminin [35] to enable tumor cell proliferation 
and instigate pro-MMPs. Cysteine cathepsins can also 
degrade  collagen  by  intracellular  proteolysis.  Colla-
gen can be taken up by macrophage and tumor cells 
via uPA and uPAR and then degraded in the lyso-
somes  by  cysteine  cathepsins  [19].  The  most  re-
searched cathepsins, cathepsins B and L, are shown to 
be  overexpressed  via  gene  amplification,  transcript 
variants expressed by tumor cells, transcription fac-
tors and post-transcriptional regulation [37].  Cathep-
sin B has been identified in membrane caveolae, out-
side of the lysosome, of human colon cancer cells and 
hypothesized to mediate further cell-surface and ECM 
degrading  proteolytic  events  [38].  Recent  work  has 
shown  that  the  permeabilization  of  the  lysosomal 
membrane is implicated in cancer, mostly due to the 
discharge of many cysteine cathepsins from their in-
nate location [39]. Once the cathepsins exit the cell and 
into the extracellular environment of tumors they can 
be  activated  by  the  acidic  conditions  found  in  the 
tumor  microenvironment  [40].  However,  different 
mechanisms of activation are also possible. Cathepsin 
K  is  shown  to  be  activated  by  glycosaminoglycans 
while cathepsins B, L and S are secreted in active form 
[41]. Interestingly, cysteine cathepsins, like cathepsins 
B, H, L, S, and K [42], translocate to the intracellular 
cytosol  without  membrane  association  to  initiate 
apoptosis  [43-44].  Some  cathepsins  have  exhibited 
protective roles [2], like cathepsin L [45]. Therefore, 
prodrug activation by cathepsins may prove to be a 
good  approach  for  anticancer  drug  delivery  over 
therapies inhibiting proteases, which are relevant for 
normal cell function. Overexpression of the cysteine 
cathepsin  is  well-documented  in  many  aggressive 
forms  of  cancer  [46],  thereby  giving  drug-cathepsin 
substrate conjugates an opportunity to be activated in 
cancerous environments and delivering chemothera-
peutics directly to the site of need. 
Cathepsin E and lysosomal cathepsin D are ho-
mologous aspartic proteases that play an equally im-
portant role in protein turnover in the cell as cysteine 
cathepsins.  Aspartic  proteases  are  made  up  of  14 
families but all usually exist in highly acidic condi-
tions, like in lysosomes or in the digestive tract. Ca-
thepsin D is found in the lysosome and is implicated 
in prostate [47], breast [48] and colorectal cancer [49]. 
Cathepsin D expression and secretion parallel many 
of the lysosomal cysteine proteases mentioned above. 
Cathepsin E, on the other hand, is not found in lyso-
somes but in the intracellular space like endosomal 
structures,  endoplasmic  reticulum  and  Golgi  appa-
ratus, as well as in the plasma membrane and pre-
dominantly  associated  with  immune  cells  [50].  Ca-
thepsin E overexpression has been associated in sev-
eral forms of cancer like human gastric [51], cervical 
[52],  pancreatic  [53-54]  adenocarcinomas  and  lung 
carcinomas [55]. To date, most developed PAPs focus 
on cathepsin B because of their expression in the in-
tracellular lysosomes. 
2.2 Kallikrein and other serine proteases 
Kallikreins  are  serine  proteases  that  are  tradi-
tionally  linked  to  poor  clinical  prognosis  of  human 
carcinoma. The most popular is prostate specific an-
tigen (PSA), also known as human kallikrein 3 (hK3) 
that  serves  as  a  diagnostic  biomarker  for  prostate 
cancer. Serine proteases mediate substrate cleavage by 
histidine, serine and aspartic acid amino acids, which 
are usually close to one another and hKs additionally 
contain 10-12 cysteine residues. Tissue kallikrein gene 
(KLK) expression  is  highly regulated by sex-steroid 
hormones [15], like androgen regulation of KLK2 and 
KLK3 [56], but there are also post-translational regu-
lations  to  control  the  irreversible  protease  action. 
Proteolytic activity of hKs can be inhibited by interac-
tions with plasma globulin, serpins, tissue inhibitors, 
zinc ions [57] as well as by its own fragmentation [15]. 
The pro-enzyme can be activated by intracellular or 
extracellular  hydrolysis  or  by  other  hKs  [15].  Kal-
likreins  are  found  in  sweat,  milk,  saliva,  seminal 




they are mainly secreted from epithelial cells in skin, 
breast, prostate, pancreas and brain. Under diseased 
conditions like cancer, hKs are dysregulated. In ovar-
ian  cancer,  for  example,  twelve  KLK  genes  are  up-
regulated [15]. However, emerging data indicates that 
hKs can both promote and inhibit tumor progression 
and is most likely dependent on hormone balances as 
well as the tissue type. This also makes determining 
its substrate a challenge as it may be tissue specific 
[58]. Otin et al. discusses the tumor suppressing roles 
of hK3, hK8, hK9, hK10, hK13, hK 14 [2]. Yet, it is the 
overexpressed hKs in different cancers that can serve 
as viable targets for drug delivery. 
A variety of hKs have been implicated in cancer 
progression like angiogenesis, invasion and metasta-
sis,  especially  with  its  interaction  with  other  serine 
proteases such as uPA and uPAR. But no hK has got-
ten as much attention as PSA (hK3) and hK2 in their 
role  in  prostate  cancer.  PSA  can  promote  prostate 
tumor growth by numerous proposed pathways like 
the  initiation  of  growth  factors  and  proteolytic  cas-
cades to degrade the ECM. PSA and hK2 are identi-
fied as insulin-like growth factor (IGF) binding pro-
tein proteases [59]. When they degrade the binding 
protein in the tumor microenvironment, they in turn 
increase the bioavailability of IGF. The growth factor 
can then easily stimulate the growth of prostate can-
cer cells. Additionally, hK2 and hK4 can activate the 
uPA proteolytic cascade by inactivating the plasmin-
ogen activator inhibitor 1 [60-62]. Without the inhibi-
tor, uPA can bind to its receptor, uPAR, and convert 
plasminogen  to  plasmin,  a  serine  protease.  Plasmin 
then  leads  to  ECM  degradation  by  activation  of 
pro-MMPs and release of growth factors, like endo-
thelial  growth  factor  to  promote  angiogenesis  [63]. 
Yet, the angiogenic properties of PSA are still debated; 
works show that PSA can activate tumor growth fac-
tor β (TFGβ) to promote angiogenesis [64] but also can 
block  fibroblast  growth  factor  2  and  inhibit  angio-
genesis  [65].  Furthermore,  hKs  can  directly  activate 
ECM degrading MMPs, like type IV collagenases [66]. 
The uPA-uPAR pathway is a well studied mechanism 
of  cancer  progression  [67-69],  and  offers  many  op-
portunities  to  target  proteases  like  PSA,  hK2,  uPA, 
plasmin and MMPs, for potential anti-cancer therapy. 
Elevated levels of uPA and its related serine proteases 
have been observed in various cancers like colorectal 
[70],  gastric  [71],  prostate  [72],  and  cervical  cancer 
[73].  Protease-activated  receptor  (PAR)  signaling  is 
another pathway that has been implicated in various 
cancers. PAR is a G-protein coupled receptor that is 
expressed in many cancer cells and cells in the mi-
croenvironment  of  a  tumor.  It  can  be  activated  by 
serine proteases like trypsin [74] and thrombin [75] by 
cleavage  of  its  extracellular  segment  and  transmit 
intracellular  signals  to  stimulate  cancer  cell  growth 
[76-78]. A comprehensive review on hKs and its role 
in  cancer  with  tabulated  clinical  implications  are 
found in references [15] and [58], respectively. 
 2.3 Caspases 
Caspases are intracellular cysteine proteases that 
are fundamental in programmed cell death – apopto-
sis [79]. They are one of the more specific and efficient 
proteases [80]. Cancer cells can suppress caspase ex-
pression to circumvent apoptosis in order to prolifer-
ate. Yet, some aggressive tumors undergo spontane-
ous apoptosis [81]. Inhibitors of apoptosis proteins are 
regulators of the caspase cascade, specifically caspase 
3 and 7, and have a large role in cancer [82]. Addi-
tionally, genetic factors such as deletion of caspase 8 
and 10 genes and mutations in caspase 3, 5, 6 and 7 are 
associated with human tumors [2]. Caspases can serve 
as interesting proteases to study the mechanisms of 
cell death and a key hallmark of cancer, but its sup-
pression rather than overexpression is what governs 
cancer progression.  
2.4 Matrix metalloproteinases 
The  most  established  extracellular  and  pericel-
lular  proteases  identified  in  cancer  metastasis  and 
many  other  diseases  are  matrix  metalloproteinases 
(MMPs). MMPs make up a versatile family of prote-
ases  that  control  many  physiological  functions  [83]. 
But as seen in the previous sections, MMPs are acti-
vated by many other proteases and serve as the pro-
teolytic  endpoint  for  tumor  progression.  As  their 
name  suggest,  MMPs  modulate  and  regulate  the 
ECM.  They  are  associated  with  different  stages  of 
cancer  invasion  and  metastasis  by  releasing  cancer 
cells to spread and provide room for cancer cells to 
invade. Additionally, ECM remodeling is involved in 
releasing many important proteins such as cytokines, 
growth factors and chemokines, and in turn MMPs 
regulate many of these proteins. MMPs can be identi-
fied by the presence of Zn2+ ions at the catalytic center 
that is coordinated by three histidine residues and a 
serine residue. They are mainly excreted as an inactive 
proenzyme and activated by a cysteine switch mech-
anism  to  expose  the  catalytic  zinc  pocket  [84].  The 
main activation system is by the removal of the pro-
domain of MMPs. As described above, proteases such 
as  plasmin,  serine  proteases  and  other  MMPs  can 
proteolytically  remove  the  prodomain  of  MMPs  to 
activate them in the extracellular space [85]. Consist-
ing of at least 23 known human enzymes, the MMP 
family  can  be  divided  into  five  sub-groups:  Colla-




Stromelysins: MMP-3, -10, -11; Membrane-type MMPs 
(MT-MMPs):  MMP-15,  -16,  -17,  -24,  -25  and  the  re-
maining proteases make up a varied group. The fam-
ily is versatile and some MMPs have shown protective 
effects  like  MMP-8,  -12,-26  and  tumorigenic  effects 
like MMP-9, -11 and more.  
Additionally  MMPs  have  been  implicated  in 
regulatory  functions  like  survival,  angiogenesis,  in-
flammation and signaling as well as other pathologies 
like  multiple  sclerosis,  stroke,  Alzheimer’s  disease, 
lung emphysema, arthritis and infections of the cen-
tral  nervous  system  [86].  The  versatility  in  MMPs 
comes from their ability to cleave multiple types of 
elements.  For  example  the  gelatinase  MMP-2  can 
cleave gelatin, type I, IV and I collagens, elastin, and 
vitronectin  [87].  MMP-9  can  also  degrade  similar 
substrates as MMP-2, except collagen I, and release 
vascular endothelial growth factor to induce neovas-
cularization. Gelatinases, MMP-2 [88] and -9 [89], are 
implicated in angiogenesis. Many papers have related 
gelatinases to tumor metastasis and angiogenesis be-
cause  of  their  ability  to  degrade  the  vascular  basal 
membrane to induce growth of new blood vessels as 
well as release growth factors responsible for tumor 
growth  [90].  Increased  expression  of  gelatinase  has 
been observed in many various cancers such as breast 
[91-93], ovarian [94], lung [95] and colorectal [96] as 
well as malignant gliomas [97-98]. MMP-2 and -9 can 
be  activated  by  MMP-7,  a  protease  that  by  itself  is 
associated with cancer cell growth because of its abil-
ity to cleave insulin-like growth factor-binding pro-
tein. In addition, MMP-7 is a special MMP because it 
can be produced by cancerous cells [99], which in turn 
further  induces  cancer  invasiveness  by  activating 
other metastasis associated proteases [100]. Although 
MMP-14 is a membrane-type MMP, it is also associ-
ated with similar substrates as gelatinases and release 
of vascular endothelial growth factor. Furthermore, it 
aids  in  decreasing  cell  adhesion  by  cleaving  mem-
brane  proteins  like  integrins,  E-cadherin,  and  cell 
surface  proteoglycans.  MMPs  make  up  a  versatile 
family  with  broad  substrate  specificity  that  are 
strongly associated with tumor progression. Although 
many  treatments  involving  MMP  inhibitors  have 
historically failed [101], increased MMP expression at 
tumor sites can play an important role in drug deliv-
ery.  Excellent  reviews  on  MMPs  and  their  clinical 
implications are found in references [85, 102-104]. 
2.5 Proteases in neurodegenerative, pulmonary 
and cardiovascular diseases 
As seen above, irregular protease signaling leads 
to dysregulation of homeostasis and can lead to can-
cer. Since proteases are regulatory enzymes and are 
required for normal cell function, their alterations can 
also lead to disorders beyond cancer. Proteases have 
been implicated in diseases such as neurodegenera-
tive, pulmonary and cardiovascular. 
Proteases are getting increasing attention in their 
role in Alzheimer’s disease (AD), a neurodegenerative 
disorder that affects approximately 2% of the popula-
tion in industrialized countries [105]. The pathological 
phenotype of AD is characterized by amyloid plague 
build up and neurofibrillary tangles in various areas 
of the brain [106]. These plagues are believed to occur 
due  to  elevated  levels  of  neurotoxic  amyloid  beta 
protein that can damage synapses and neuritis [105]. 
The proteolytic processing of the amyloid beta protein 
from  amyloid  precursor  protein  (APP)  is  the  pre-
dominant  abnormality  in  AD  [105].  APP  is  a  large 
glycoprotein that can be cleaved and activated to am-
yloid  beta  protein  by  two  aspartic  proteases, 
β-secretase at the N-terminus and γ-secretase at the 
C-terminus.  Additionally,  α-secretase,  a  disintegrin 
and metalloproteinase domain protease (ADAM), is 
known to cleave APP within the important amyloid 
beta protein sequence [105]. The ADAM family (made 
up of 21 known human ADAMs [107]) has adhesive 
and proteolytic properties, which can aid in mediat-
ing interaction with  other molecules as well as sig-
naling. This family is an emerging field and more re-
search is needed to implicate these MMP-type prote-
ases in various pathologies.  An inhibitory and im-
munization  treatment  has  shown  that  a  removal  of 
amyloid beta protein deposits can recover cognitive 
defects associated with AD [108-109]. Therefore, pro-
teases  that  are  directly  associated  with  amyloid 
plaque formation in AD can serve as promising ther-
apeutic targets. Several proteases have shown to be 
elevated in AD, but their use as diagnostic or prog-
nostic  biomarkers  are  still  in  preliminary  stages 
[110-111]. Additionally, elevated levels of other MMP 
types have been seen in AD [112] along with varying 
neurological conditions like stroke (MMP-9) [113-114] 
and HIV associated dementia (MMP-2, -7, -9) [115]. 
Beyond MMPs, caspase overexpression has also been 
implicated in neurodegenerative disorders [82]. 
Because of MMPs’ role in ECM remodeling and 
angiogenesis, their dysregulation can lead to pulmo-
nary  and  cardiovascular  disorders.  The  gelatinase 
family of MMPs (MMP-2, -9), are implicated in many 
fibrous pulmonary diseases like chronic asthma [116], 
cystic fibrosis, bronchiectasis, and chronic obstructive 
pulmonary disease (COPD) [87]. This may be due to 
dysregulation of ECM remodeling leading to a thick-
ening of the basement membrane. Protease signaling 
pathway is involved in the blood coagulation cascade 




to  cardiovascular  disease.  The  specific  roles  that 
gelatinases  play  in  angiogenesis  has  lead  others  to 
hypothesize their role in vasoconstrictive properties 
and disorders such as hypertension [117]. Angioten-
sin-converting enzyme (ACE) is a metalloproteinase 
that  is  central  to  the  blood  coagulation  cascade  by 
converting angiotensin I to angiotensin II, required for 
angiotensin receptor activation and vessel constriction 
[118]. The use of ACE inhibitors have been used on 
the  market  for  over  20  years  to  treat  hypertension, 
heart  failure  and  heart  attack  [119].  Outside  of  the 
MMP family, hK1 is implicated in kinin production, 
which  can  mediate  many  biological  functions  like 
inflammation  and  hypertension  [120].  Additionally, 
cathepsins have been found to be relevant biomarkers 
in various diseases beyond cancer, like lung and brain 
diseases and atherosclerosis [121]. Further reading on 
the use of proteases as biomarkers and targets in dis-
eases outside of cancer can be found in reference [3] 
and references within. 
Proteases are important regulatory molecules in 
our body. Their proper function is needed for appro-
priate  protein  turnover  and  signaling.  However, 
when these proteases are unbalanced their irreversi-
ble actions can greatly affect normal cellular function 
and lead to pathologies like cancer and neurodegen-
erative,  pulmonary  and  cardiovascular  diseases. 
Many  studies  have  suggested  the  use  of  different 
proteases as biomarkers and prognostic markers for 
such diseases.  Furthermore, protease inhibitors have 
been  developed  to  stabilize  protease  function.  Here 
we briefly introduced key human proteases that have 
been found to be overexpressed in various patholo-
gies,  specifically  cancer.  Furthermore,  we  describe 
how  they  are  deregulated  and  list  the  proteases 
commonly implicated in various forms of disorders 
(Table 1). We hope that this protease introduction can 
serve to educate readers on potential drug targets and 
how their overexpression can be utilized for specific 
drug delivery by PAPs. 
3. Protease-Activatable Prodrugs 
Prodrugs  are  chemically-caged  derivatives  of 
therapeutic agents that can be transformed by an en-
zyme, chemical or physiological stimuli to release the 
active parent drug in vivo [12]. From the time the term 
prodrug  was  first  coined  by  Adrien  Albert  in  1958 
[122], a wide variety of prodrugs has been extensively 
investigated. The prodrug approach generally aims to 
i) improve the physicochemical properties of parent 
drug molecules, such as low chemical stability or poor 
water-solubility;  ii)  improve  their  pharmacokinetic/ 
pharmacologic  properties,  like  insufficient  oral  ab-
sorption,  unwanted  rapid  metabolism  or  low  selec-
tivity; and also iii) reduce undesirable irritation, pain 
or non-specific toxicity to normal tissues [12-13]. 
Prodrugs have minimal pharmacological effects 
in its native state. However, pharmacological activity 
is recovered when they are transformed into the ac-
tive parent drug or its derivative by disease-specific or 
environmental  stimuli.  Among  various  targets  of 
prodrugs, proteases are considered an important tar-
get because proteases are highly involved in diseases 
as described in Section 2 above. For PAPs to be effec-
tive,  the  linkage  between  the  drug  and  promoiety 
should remain stable in the bloodstream but degrade 
once it reaches its target protease. Peptide sequences, 
which are stable in the blood but highly specific to-
wards target proteases, have been developed. To fa-
cilitate delivery of therapeutic agents to the target site, 
targeting moieties (e.g. antibody) or macromolecular 
carriers (e.g. albumin or polymers) are coupled to the 
peptide-based  prodrugs.  Therefore,  in  most  cases, 
prodrugs are composed of two major components: i) 
an active therapeutic agent and ii) peptide substrates 
and/or  macromolecular  carriers,  i.e.  promoiety.  To 
endow prodrugs with target-specificity, they can also 
be modified with additional iii) targeting ligands [12, 
123]. In other words, the parent therapeutic agent is 
caged  by  the  promoiety  and/or  modified  with  the 
targeting ligand via target-specific, cleavable linkages 
(Fig.  1).  Prodrugs  activated  by  proteolysis  have  at-
tracted much attention in the field of drug discovery 
and development. In this section, representative PAP 
approaches  including  peptide-based  prodrugs  and 
macromolecular prodrugs will be briefly exemplified. 
 
3.1. Cathepsin-Activatable Prodrugs 
Proteases are known to selectively cleave specific 
substrates, e.g. an amino acid or peptide sequences. 
The  fact  that  proteases  can  recognize  and  degrade 
specific substrates sheds light on the development of 
prodrugs that can be activated at target disease sites. 
Among proteases, cathepsins are well-known prote-
ases  that  are  upregulated  in  several  tumor  tissues 
(Table  1).  Overexpressed  cathepsins  are  considered 
important biomarkers for cancer and can serve as key 
targets for prodrugs to induce anticancer drug release 
to tumor tissues or inside tumor cells.   
Initial  works on protease prodrugs focused on 
conjugating  single  amino  acids  or  dipeptides  onto 
common cancer therapeutic drugs like daunorubicin 
(DNR) or doxorubicin (DOX) to study their increased 
therapeutic effects.  





Fig. 1 Schematic diagram of (A-E) prodrug constructs and (F) hypothetical pathway of prodrug activation 
 
For  example,  amino  acid-  and  dipep-
tide-daunorubicin conjugates (L-Leu-DNR, Val-DNR, 
Ile-DNR,  Ala-Leu-DNR  and  Leu-Leu-DNR)  were 
prepared to investigate the effect of modification of 
DNR  on  its  toxicity  and  antitumor  efficacy  toward 
murine  L1210  leukemia  [124].  When  intravenously 
administrated  into  L1210  leukemia  xenografts, 
Leu-DNR, Ala-Leu-DNR and Leu-Leu-DNR exhibited 
superior results on the suppression of tumor growth 
to DNR and on the survival rate. Leu-DNR accumu-
lated in the heart muscle much less than DNR at eq-
uitoxic  doses  in  the  rabbit,  and  therefore  exhibited 
reduced  cardiotoxicity,  a  major  side  effect  of  an-
thracycline derivatives. Similarly, Leu-DOX prodrugs 
were also developed to lower the cardiotoxicity and 
improve  the  therapeutic  index  of  DOX  [125-130]. 
Compared to DOX alone, Leu-DOX had higher anti-
tumor efficacy together with lower toxicity in various 
tumor-bearing mice including human ovarian, breast 
and  lung  carcinoma  models.  Notably,  it  was  sug-
gested that superior antitumor efficacy of Leu-DOX to 
DOX  is  due  to  their  enhanced  hydrophobicity  and 
also to their proteolysis in tumor tissue by proteases 
such as cathepsins, which are known to be highly ex-
pressed in several tumor tissues (Table 1). However, 
the studies did not show any direct evidence of pro-
teolysis of the leucyl group by cathepsins. 
Follow up studies investigated the peptide sub-
strates, proteolysis mechanisms and prodrug delivery 
agents  like  albumin  and  macromolecules  on  cancer 
therapeutic effects. DNR or DNR derivatives (DNR, 
Leu-DNR,  Ala-Leu-DNR,  Leu-Ala-Leu-DNR  or 
Ala-Leu-Ala-Leu-DNR) were further conjugated onto 
albumin  (ALB)  [131].  Remarkably,  when  the  DNR 
prodrugs  were  incubated  with  lysosomal  enzymes, 
active  DNR  molecules  were  released  from 
ALB-Leu-Ala-Leu-DNR  and  ALB-Ala-Leu-Ala-Leu- 




ALB-Ala-Leu-DNR. However, in the presence of 95% 
calf  serum,  ALB-Leu-Ala-Leu-DNR  and 
ALB-Ala-Leu-Ala-Leu-DNR  were  over  97%  stable 
after 24 h incubation. Likewise, in the intraperitoneal 
L1210  leukemia  model,  the  ALB-tri-/tetra-peptide- 
DNR  prodrugs  were  proven  to  be  superior  to 
mono-peptide linkers, with improved anticancer ac-
tivity  and  prolonged  survivals.  From  the  results,  it 
was  proposed  that  the  ALB-tri-/tetra-peptide-DNR 
prodrugs internalize into leukemia cells and release 
parent  DNR  molecules  inside  the  cells  because  of 
proteolysis  of  the  peptide  substrates  by  lysosomal 
proteases, like cathepsin B. 
Besides  albumin,  macromolecules  have  been 
vigorously investigated as potent drug-delivery car-
riers. Owing to the abnormal characteristics of tumors 
like leaky blood vessels and lack of lymphatic drain-
age, macromolecules are known to preferentially ac-
cumulate in tumor tissue and remain for a prolonged 
period of time, the so called enhanced permeable and 
retention  (EPR)  effect  [132-133].  In  an  effort  to  im-
prove blood stability and tumor targetability of pro-
drugs,  macromolecule-based  prodrugs  have  been 
developed.  As  an  example,  N-(2-hydroxypropyl) 
methacrylamide copolymer (HPMAcp) was exploited 
as  a  macromolecular  carrier  to  deliver  therapeutic 
agents or their derivatives. Onto the HPMAcp back-
bone, DOX was conjugated via a cathepsin B-specific 
tetrapeptide (Gly-Phe-Leu-Gly) linker [134-140]. After 
intravenous  administration,  the  macromolecular 
prodrug  circulated  approximately  15-times  longer 
than free  DOX. Furthermore, the prodrug exhibited 
100-times  less  heart  uptake,  which  resulted  in  de-
creased  toxicity  and  improved  therapeutic  efficacy 
compared with free DOX. Interestingly, the pharma-
cokinetics and amount of released DOX was found to 
be correlated with both lysosomal activity of cathep-
sin  B  and  vascular  properties  (Fig.  2)  [135]. 
 
 
Fig. 2 (A) Chemical structure of PK1 (HPMAcp-Gly-Phe-Leu-Gly-DOX). DOX concentrations in MAC15A (◯) and MAC26 (□) plasma 
(dotted line) and tumor (solid line) after administration of 10 mg/kg DOX i.v (B) or 490 mg/kg PK1, i.v. (40 mg/kg DOX equivalent) (C). 
Antitumor effects of DOX or PK1 against MAC26 tumors (D), MAC15A (E and F). ◯, PK1 (40 mg/kg); □, PK1 (20 mg/kg); △, PK1 (10 
mg/kg); ▽, dox (10 Mg/kg); ◇, controls. Adapted with permission from Loadman et al [135]. Copyright 1999, American Association for 




This study implies that highly-activated cathep-
sin B can induce vascularization around tumors and 
accelerate DOX release. Most importantly, the study 
exemplifies that a protease can enhance the therapeu-
tic efficacy of a macromolecular prodrug. However, 
the study could not elucidate whether the excellent 
therapeutic  efficacy  was  attributed  to  DOX  release 
activated by cathepsin B or a higher accumulation of 
the prodrug through highly vascularized tumor ves-
sels.  With  the  apparent  enhanced  drug  efficacy, 
HPMAcp  was  also  conjugated  to  DNR  [141], 
5-fluorouracil  (5-FU)[142],  platinum  (II)  [143]  and 
O-(chloracetyl-carbamoyl) fumagillol (TNP-470) [144] 
via the same peptide linker (Gly-Phe-Leu-Gly). Just as 
the DOX conjugate, these formulations also showed 
significant therapeutic activity to free drugs. 
A significant example of cathepsin B-activatable 
prodrugs utilized a polymerized substrate to reverse 
cancer  progression,  emphasizing  the  use  of  macro-
molecular  protease  substrates  for  efficient  drug  de-
livery  and  effective  therapy.  The  cathepsin 
B-activatable  prodrug,  poly(L-glutamic  acid)  conju-
gated with paclitaxel (PTX), exerted impressive anti-
tumor activity in OCA-1  ovarian carcinoma models 
[145].  Notably,  a  single  intravenous  injection  of  the 
macromolecular  prodrug  resulted  in  the  disappear-
ance of 13762F adenocarcinoma implanted in rats and 
OCA-1 ovarian carcinoma inoculated in rats. The ex-
cellent  antitumor  activity  possibly  resulted  from  its 
prolonged half-life in plasma and preferential accu-
mulation  of  released  PTX  in  tumor  tissue.  In  a  fol-
low-up study, the metabolic pathway of the macro-
molecular  prodrug,  poly(L-glutamic  acid)-PTX  was 
investigated [146]. The study demonstrated that it can 
be metabolized into mono- or di-glutamyl-PTX form 
after it internalizes into cancer cells. The release rate of 
PTX is correlated with the proteolytic activity of ca-
thepsin  B.  The  metabolism  of  poly(L-glutamic  ac-
id)-PTX was inhibited in cathepsin B deficient mice or 
by administration of cathepsin B inhibitor in mice. 
Although  cathepsin  B  is  a  common  protease 
target for prodrugs (Table 2), its proteolytic activity 
needs  to  be  examined  more  closely.  For  example, 
previous works have shown that cathepsin B can be 
released to the extracellular space in active form un-
der certain pathologies (Section 3.1). This may cause 
premature activity of the prodrug and reduce its effi-
cacy inside tumor cells. However, cathepsin activata-
ble prodrugs are exemplary in their roles for thera-
peutic delivery because these PAPs are shown to be 
much  more  efficient  than  equitoxic  doses  of  free 
drugs. It is important to consider additional molecules 
for proper drug delivery, especially when the prote-
ase of interest in found intracellularly. In the above 
examples, the use of macromolecular substrates or the 
addition of albumin greatly increased the delivery of 
the prodrug to its target site. 
 
3.2. PSA-activatable prodrugs 
The  peptide  sequence  (Ser-Ser-Lys-Leu-Gln)  is 
highly specific for PSA [147]. The peptide substrate 
has  been  coupled  with  DOX  to  develop  a 
PSA-activatable  prodrug  [148-149].  The  resulting 
prodrug  (morpholinocarbonyl(Mu)-Ser-Ser-Lys-Leu- 
Gln-DOX)  exerted  severe  cytotoxicity  not  only  to 
PC-82 human prostate cancer cells, that secrete high 
levels  of  PSA,  but  also  to  LNCaP  human  prostate 
cancer cells, that secrete 30 fold less active PSA. Yet 
following 72-h incubation with LNCaP cells, over 90% 
of the prodrug was activated to release Leu-DOX and 
killed 50% of cells at a low concentration (IC50 = 70 
nM). Importantly, the drug did not show detectable 
toxicity  to  PSA-nonproducing  cells,  TSU  human 
prostate cancer cells, which indicates great sensitivity 
of  the  PSA-activatable  prodrug.  When  the  prodrug 
was given by continuous infusion into PC-82 human 
prostate cancer xenografts at a high dose (four times 
higher  than  the  100%  lethal  dose  of  free  DOX),  no 
noticeable  toxicity  was  observed.  Moreover,  an  in-
traperitoneal  injection  of  the  prodrug  suppressed 
tumor growth up to 57% in tumor weight compared 
with the non-treated control group. The continuous 
infusion  with  the  prodrug  also  led  to  similar  sup-
pression activity on tumor growth (47% lower than 
control  group  in  tumor  weight)  at  60%  lower  dose 
than the dose administrated intraperitoneally. In the 
same  way,  thapsigargin  (TPG)  [150-151]  or 
5-fluorodeoxyuridine  (5-FudR)  [152]  were  coupled 
with  the  same  PSA-specific  peptide  substrate.  The 
PSA-activatable  prodrugs  also  exhibited  remarkable 
inhibitory effects on tumor growth without discerni-
ble toxicity after intravenous administration. 
Another  peptide  substrate  (N-glutaryl- 
(4-hydroxyprolyl)-Ala-Ser-chGly-Gln-Ser-Leu)  spe-
cific for PSA was also discovered and exploited for the 
development  of  PSA-activatable  prodrugs  (Fig.  3) 
[153]. In this research, DOX was covalently incorpo-
rated  with  PSA-specific  peptide  sequence.  The  re-
sulting conjugate was hydrolyzed specifically by PSA 
and  transformed  into  cytotoxic  form  of  DOX,  leu-
cine-DOX and DOX. Like other prodrugs, it was much 
less toxic than free DOX to PSA-negative cells; how-
ever, it led to remarkable reduction in tumor burden 
in human prostate cancer xenografts inoculated with 
either LNCaP or CWR22. 





Fig. 3 (A) Chemical structure of L-377,202. Changes in concentrations of leucine–DOX and DOX in tumor tissue (B) and heart tissue 
(C). ◆, DOX from L-377,202;  ●, leucine–DOX from L-377,202; ◇, DOX from administration of conventional DOX. (D) Reduction in 
LNCaP tumor weights in nude mice treated with DOX or L-377,202. Adapted with permission from DeFeo-Jones et al [153]. Copyright 
2000, Nature Publishing Group 
 
Macromolecules,  such  as  ALB  and  HPMAcp, 
were also combined with therapeutic agents like TPG 
or  DOX  via  PSA-specific  substrates.  In  a  macromo-
lecular  prodrug  system,  the  same  peptide  sequence 
previously described (Mu-Ser-Ser-Lys-Leu-Gln), was 
used as a linker to conjugate TPG derivative named 
L12ADT onto  the HPMAcp backbone  [154].  In an-
other system, DOX was coupled with ALB via a sim-
ilar  peptide  substrate  (ε-maleimidocaproic  acid 




[155-156]. PSA selectively cleaves the substrate, con-
verting inactive prodrugs into active forms of parent 
drugs  or  their  derivatives.  As  an  example, 
ALB-EMC-Arg-Arg-Ser-Ser-Tyr-Tyr-Ser-Arg-DOX 
exerted  enhanced  suppression  of  tumor  growth  by 
62% in tumor size over free DOX. Additionally, the 
prodrug showed no sign of detectable toxicity after 
administration  of  equimolar  DOX  into  a  prostate 
cancer model orthotopically implanted with LNCaP 
LN prostate cancer cells. More interestingly, admin-
istration of the prodrug reduced the metastatic bur-
den in the lungs by 50%. 
3.3. MMP-activatable prodrugs 
MMPs  are  representative  target  protease  for 
prodrugs  that  may  arguably  be  the  most  studied 
proteases. Because they are found in the extracellular 
and pericellular areas of the cell, MMPs can serve as 
excellent protease targets for prodrug delivery to the 
tumor microenvironment. Although a versatile fami-
ly, specific substrates have been discovered that can 
be cleaved by a limited amount of MMPs. In particu-
lar,  the  progression  of  various  malignancies  can  be 
characterized by the overexpression of MMP-2 [2].  
Like  the  other  prodrugs  described  above, 
MMP-activatable prodrugs have been developed by 
chemical conjugation of MMP-cleavable peptide sub-
strate  (Glu-Pro-Cit-Gly-Hof-Tyr-Leu)  to  DOX 
[157-158].  The  peptide  substrate  was  specifically 
cleaved by MMP-2, -9, -14. Interestingly, it was found 
that the peptide substrate was initially metabolized by 
neprilysin,  a  membrane-bound  metalloproteinase, 
when they were incubated with an MMP-expressing 
fibrosarcoma cell line, HT1080. In HT1080 xenografts, 
the  substrate  was  preferentially  metabolized  in  the 
tumor tissue, resulting in a 10-fold higher accumula-
tion  of released DOX at the tumor than  that in the 
heart.  When  this  MMP-substrate  prodrug  was  ad-
ministered to mice, 80% of mice were cured and no 
significant toxicity was detected, such as weight loss 
or marrow toxicity.  
Since MMP-2, -9 specifically cleave the peptide 
sequence  Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln,  the  pep-
tide substrate was also used to design a DOX prodrug 
that  can  be  specifically  activated  by  MMP-2  [159]. 
ALB was incorporated with the peptide-DOX conju-
gate  as  a  carrier.  The  intact  albumin-peptide-DOX 
conjugate  was not  significantly toxic.  However, fol-
lowing addition of MMP-2, the albumin-peptide-DOX 
conjugate released tetrapeptide-DOX and was further 
transformed  into  the  parent  anticancer  drug,  DOX. 
The prodrug was 4-fold less toxic than free DOX in 
vivo, whereas it showed superior anticancer effect to 
DOX at an equitoxic dose.  
Just  as  tumor-specific  chemotherapeutics, 
MMP-activatable prodrugs can be improved by uti-
lizing a macromolecular carrier. For example, meto-
traxate (MTX) was conjugated onto a macromolecular 
carrier, dextran (DEX) via an MMP-specific peptide 
linker  (Pro-Val-Gly-Leu-Ile-Gly)  (Fig.  4)  [160-161]. 
This  macromolecular  prodrug  shows  specificity  to 
MMP-2 and -9 and releases peptidyl-MTX when in-
cubated  with  targeted  proteases;  however,  it  re-
mained  stable  in  serum.  This  study  illustrated  that 
macromolecular  prodrugs  preferentially  accumulate 
in tumor tissues by the EPR effect more than free MTX 
and then release MTX derivatives close to or within 
tumor tissues. Importantly, the amount of tumor ac-
cumulation  in  vivo  was  not  significantly  correlated 
with the specificity of peptide substrates, even though 
the peptide sequence was proven to be highly specific 
in  vitro.  The  unexpected  results  suggest  that  since 
there is a great number of endo- and exopeptidases in 
the human body, the in vivo properties, such as stabil-
ity in the bloodstream and the specificity to the target 
protease, should be carefully considered.  
MMP  overexpression  is  linked  to  numerous 
cancers  (Table  1).  Their  role  in  ECM  remodeling  is 
required  for  cancer  cells  to  metastasize  and  invade 
different locations. Therefore MMP-specific prodrugs 
can especially target metastasized forms of cancer. A 
drawback to MMP targeting is their cleavage of vari-
ous substrates by multiple types of MMPs. The ex-
emplified  prodrugs  in  this  section  utilized  unique 
peptide  sequences  but  still  targeted  more  than  one 
MMP. Although this may be a limitation for molecu-
lar  biology  in  order  to  identify  a  specific  form  of 
MMP, multiple-MMP targeted prodrugs can be used 
to  deliver  anticancer  drugs  to  especially  harmful 
forms of cancer.  
3.4. Targeted protease-activatable prodrugs 
As we reviewed in the previous sections, PAPs 
are generally inactive but become pharmacologically 
active when exposed to target proteases. Owing to its 
improved  stability  and  target-specific  drug  release, 
prodrugs  have  a  wide  therapeutic  window  when 
compared to free chemotherapeutic agents. However, 
in  terms  of  the  targeting  mechanism,  most  conven-
tional prodrugs are still limited because they mainly 
rely on passive accumulation pathways, e.g. EPR ef-
fect. In an effort to bestow disease-specific targetabil-
ity  upon  prodrugs,  various  targeting  moieties,  e.g. 
antibody,  peptide  or  oligonucleic  acid  molecules, 
have been employed.  
For  instance,  therapeutic  agents  have  been  co-
valently  conjugated  with  disease-specific  antibodies 




tumor-specific recognition site and a tumor selective 
enzymatic  activation  sequence  in  a  single  prodrug 
platform. The antibody-drug conjugates (ADCs) have 
come a long way and shown significant therapeutic 
efficacy against various diseases [162-163]. An inter-
esting  study  demonstrates  the  development  and  in 
vivo  applications  of  a  cathepsin  activated  ADC.  A 
synthetic dolastatin 10 analog, monomethyl auristatin 
E (MMAE), was incorporated onto an antibody cAC10 
with specificity for CD30 on hematological malignan-
cies via a dipeptide substrate (Val-Cit) as a cathepsin 
B-specific  linker  (Fig.  5)  [164].  The 
mAb-Val-Cit-MMAE  conjugate  is  highly  stable  in 
plasma  but  released  active  MMAE  in  lysosomes  of 
CD30-positive tumor cells. The ADC showed higher 
specificity in vitro, lower toxicity in vivo and improved 
antitumor  effect  than  control  ADCs  containing  hy-
drazone linker. Notably, with the use of this ADC, the 
therapeutic index significantly increased up to 60-fold 
leading to its extensive investigation in the clinic. Re-
cently, the conjugate, named Adcetris (brentuximab 
vedotin)  has  been  approved  by  The  U.S.  Food  and 
Drug  Administration  (FDA)  for  the  treatment  of 
Hodgkin  lymphoma  (HL)  and  a  rare  lymphoma 




Fig. 4 (A) Chemical structure of the MTX-PVGLIG-DEX. (B) Cytotoxicity of MTX and different types of MTX-peptide analogs: MTX (△), 
MTX-G (□), MTX-GI (◯), MTX-GIV (▲), and MTXPVG (■). (C) Stability of the conjugate (MTX-PVGLIG-DEX) in various media con-
ditions. Tissue distribution of MTX equivalent in mice receiving MTX-PVGLIG-DEX (D) and free MTX (E), at 5 h (▩) and 24 h (■) post 
injection.  Adapted with permission from Chau et al [160-161]. Copyright 2004, American Chemical Society and Copyright 2006, John 





Fig.  5 (A) Chemical structure of mAb-drug conjugates. (B) Hydrolysis of cBR96-Phe-Lys-MMAE and cBR96-Val-Cit-MMAE (eight 
drug-mAb combinations) with human cathepsin B. In vivo therapeutic efficacy of the conjugates in immunocompromised mice with sub-
cutaneous human tumor xenografts. (C) Athymic mice with subcutaneous L2987 human lung adenocarcinoma tumors (cBR96 Ag+, 
cAC10 Ag–) were treated with the conjugates. (D) SCID mice with subcutaneous Karpas 299 human ALCL tumors (cAC10 Ag+, cBR96 
Ag–) were treated with MMAE or with the mAb-Val-Cit-MMAE. (E) SCID mice with Karpas 299 tumors were treated with cAC10, cAC10 
+ unconjugated MMAE, cAC10-Val-Cit-MMAE or cBR96-Val-Cit-MMAE. Adapted with permission from Doronina et al [164]. Copyright 
2003, Nature Publishing Group 
 
 
Another example of targeted PAPs is macromo-
lecular  prodrugs,  PK1  and  PK2.  As  we  described, 
HPMAcp-Gly-Phe-Leu-Gly-DOX,  called  PK1,  is  a 
macromolecular  prodrug  targeting  cathepsin  B 
[134-135,  137-140].  When  compared  with  free  DOX, 
PK1 showed prolonged circulation, less cardiotoxicity 
and improved therapeutic activity. In addition, it was 
proposed  that  the  excellent  therapeutic  efficacy  of 
PK1 is due to the passive accumulation into the tumor 
tissue by the EPR effect and the target-specific drug 
release  by  lysosomal  degradation  of  the  peptide 
linkage.    PK2  was  further  modified  with  galactose 
(GAL)  to  facilitate  liver  targeting, 
GAL-HPMAcp-Gly-Phe-Leu-Gly-DOX.  After  intra-
venous injection of PK2, acute toxicity decreased three 
times over free DOX without noticeable signs of car-
diotoxicity.  With  these  promising  results,  PK1  and 
PK2 are now under clinical trials [166-171].  
In addition to mAb or GAL, a bicyclic peptide 
sequence,  RGD-4C  (Cys-Asp-Cys-Arg-Gly-Asp- 
Cys-Phe-Cys)  was  exploited  as  a  targeting  moiety 
[172]. RGD-4C selectively binds αvβ3 and αvβ5 integ-
rins, which are known to highly overexpress on in-




was coupled with DOX via a plasmin-specific peptide 
substrate (D-Ala-Phe-Lys). As we mentioned, plasmin 
is highly associated with tumor progression (Section 
2.2).  The  resulting  conjugate  exerted  cytotoxicity 
against  plasmin-positive  HT1080  fibrosarcoma  cells 
but not to endothelial cells, showing significant speci-
ficity to the target protease plasmin. Likewise, a cyclic 
13-mer oligopeptide named pep 42 was exploited as a 
targeting  moiety  to  develop  tumor  targeted  PAPs 
[173].  Pep  42  can  bind  to  glucose-regulated  protein 
GRP78 and facilitate cancer cell-specific uptake. An-
ticancer drug, PTX or DOX was conjugated with pep 
42 via a cathepsin B-specific cleavable linker (Val-Cit). 
The conjugates were designed to localize at lysosomes 
and to release therapeutic agents when taken up by 
the cancer cells. The targeted PAP system exhibited 
improved  anticancer  activity  against  SJSA-1  osteo-
sarcoma cells known to express GRP78.  
Overall, PAPs have shown superior pharmaco-
kinetic  properties  to  free  drug  molecules  because 
chemical  modification  can  improve  their  chemical 
stability,  hydrophilicity  and  circulation  time  in  the 
bloodstream.  More  importantly,  the  PAP  approach 
improves pharmacological properties owing to their 
preferential accumulation and release of active forms 
of therapeutic agents in target tissues or cells by pro-
teolysis. Additional modification of PAP with target-
ing molecules facilitates the accumulation and release 
of active therapeutic agents at the target site. Over the 
past half-century, a great number of PAPs have been 
invented and used in clinical settings. Based on the 
successful  examples  of  the  PAP  approach,  the  fol-
lowing section will elucidate imperative design fac-
tors in the development of PAP.  
4. Perspective on prodrug design 
Although a few PAPs have entered clinical de-
velopment already (Table 3), we further identify key 
design  elements  that  are  needed  to  develop  highly 
efficient therapeutic agents that are released in prote-
ase  overexpressed  environments.  We  acknowledge 
many  proteases  require  further  research  in  their 
physiological  roles,  but  the  overwhelming  research 
showing  their  overexpression  in  pathologies  cannot 
be ignored (Table 1). PAPs do not hamper or inhibit 
normal protease activity directly, but instead use the 
protease deregulation to identify an area that requires 
a specific form of drug. In this way, unnecessary tox-
icity to healthy cells is eliminated. The three design 
elements to consider when developing PAPs are: 1) 
stability and specificity of peptide substrate, 2) loca-
tion of drug activation, 3) addition of a delivery sys-
tem. 
First,  the  stability  and  specificity  of  a  peptide 
substrate is by far the most important element to effi-
ciently target proteases. The peptide substrate must 
remain stable in blood and plasma until it reaches its 
target protease upon which, it is cleaved to release the 
parent drug. If the peptide is not stable in these con-
ditions, the prodrug cannot be intravenously admin-
istered and does not provide any benefit over admin-
istration of the parent drug directly. The stability of 
peptide  substrates  can  be  enhanced  by  the  use  of 
macromolecular  structures,  as  seen  in  the  example 
above  of  the  polymerized  peptide  substrate  for  ca-
thepsin B. Furthermore, the prodrug should target a 
specific protease that is associated with the disease. 
This is an area that requires further research, as many 
specific substrates for proteases linked to cancer have 
not  been  identified.  For  example,  MMP  substrates 
target many different MMPs and therefore have low 
specificity for one member of the MMP family. Alt-
hough this is not necessarily a disadvantage, it may 
still reduce the efficacy of the drug and increase tox-
icity to areas that do not require the therapy. Caspa-
ses, on the other hand, have more specific substrates 
but  they  are  generally  not  seen  as  good  targets  for 
cancer  because  they  are  key  signal  molecules  for 
apoptosis, a process normally found in healthy cells 
but circumvented in cancer cells.   
 
Table 3. Protease-activatable prodrugs in the clinic 
 
*Abbreviations: cAC10: chimeric anti-CD30 monoclonal antibody, chGly: cyclohexaglycyl, Cit: citrulline, GAL: galactose, DOX: doxorubicin, HPMAcp: 
N-(2-hydroxypropyl)methacrylamide copolymer, NSCLC: non-small-cell lung cancer, MMAE: monomethyl auristatin E, PTX: paclitaxel 
Name  Protease  Construct  Indication  Status  Ref. 
Brentuximab 
vedotin (SGN-35)  Cathepsin B  cAC10-Val-Cit-MMAE  Hodgkin 
lymphoma  Approved  [162-
163] 
OPAXIO™ 
(CT-2103)  Cathepsin B  poly-L-glutamic acid-PTX  NSCLC  Phase III  [258-
260] 
PK1 
(FCE 28068)  Cathepsin B  HPMAcp-Gly-Phe-Leu-Gly-DOX  Cancer  PhaseI/II  [170] 
PK2 
(FCE 28069)  Cathepsin B  GAL-HPMAcp-Gly-Phe-Leu-Gly-DOX  Liver cancer  PhaseI/II  [167] 
L-377,202 
(C1853) 
PSA  N-glutaryl-(4-hydroxyprolyl)-Ala-Ser- chGly-Gln-Ser-Leu-DOX  Prostate 
cancer 
Phase II  [261] 




Second, location of target protease expression is 
important to recognize in order to design drug con-
jugates that can reach the specific target. In most cas-
es, drugs exert their therapeutic effect when delivered 
specifically to the intracellular space of the unhealthy 
cell.  But  certain  important  target  proteases  are  ex-
pressed extracellularly, especially under pathological 
conditions, and the PAP can be activated prematurely 
outside of the cell. In this view, prodrug constructs 
including  peptide  substrates,  therapeutic  agent  and 
targeting moiety should be designed together with the 
target protease and its active site in mind. For exam-
ple, PEG improves chemical stability and biocompat-
ibility of drug molecules and also prolongs circulation 
time  when  coupled  with  hydrophobic  drug  mole-
cules, but also reduces cellular uptake of drug mole-
cules.  In  that case, the linkage between drug  mole-
cules and PEG should be cleaved by a specific prote-
ase that is active in extracellular conditions prior to 
cellular  uptake  as  shown  in  ref  [174].  On  the  other 
hand, if a therapeutic agent works well inside target 
cells but is not stable outside the cells, the drug should 
be caged by a specific promoiety that can protect it 
until it is degraded at target compartments of the cells 
[164, 175-176]. In such cases, various targeting moie-
ties, like aptamers or antibodies and additional pro-
moieties may be helpful to target the prodrug into the 
intracellular space. Furthermore, function of the pro-
tease  in  the  type  and  stage  of  tumors  is  significant 
when designing PAPs. Most enzymes are temporal, 
for examples caspase 2 and 3 are markers of apoptosis 
but caspase 3 is only present at late stages. This may 
explain why many caspase-based probes have mainly 
served  as  sensors  for  apoptosis  over  drug  delivery 
agents. Emerging data, such as for hKs, indicate that 
their function is dependent on hormone balances as 
well as tissue type. Therefore, it is beneficial to target 
enzymes that are present throughout the entire dis-
ease progression and to understand the protease role 
in  the  specific  tissue  targeted.  A  solution  is  to  use 
combinatorial delivery approaches as described in the 
final design consideration. 
Thirdly, a delivery carrier system can be utilized 
to target the prodrug more efficiently. As seen in the 
current prodrug examples, albumin served as a stabi-
lizing  agent  for  the  therapeutic  and  also  aided  in 
prodrug accumulation by the EPR effect. Nanoparti-
cles, as seen in many drug delivery applications, can 
accumulate  in  the  tumor  by  EPR  efficiently  [177]. 
More  importantly,  nanoparticles  can  serve  as  plat-
forms for numerous moieties that can aid in PAP de-
sign  like  protease  substrates,  targeting  molecules, 
stabilizing agents, and imaging agents. In this way, a 
nanoparticle  based  approach  for  protease  targeted 
therapeutic delivery can act as multimodal imaging 
and drug delivery agent – a true theranostics agent. 
5. Conclusion 
We have introduced key proteases that are in-
volved in various pathologies, especially cancer, and 
their potential as targets for prodrugs. With a brief 
introduction  on  the  roles  of  cathepsins,  kallikreins, 
serine proteases, caspases and MMPs, we show that 
their dysregulation can be implicated in many forms 
of cancer, as well as in neurodegenerative, pulmonary 
and  cardiovascular  diseases.  Furthermore,  we  pro-
vide few examples of PAPs that have utilized specific 
proteases  to  target  intracellular  cathepsins,  PSA  (a 
type of human kallikrein), and MMPs. In this way, we 
hope to illuminate the important roles that proteases 
can  play  in  targeted  therapies  and  go  beyond  their 
functional role in molecular imaging. With our expe-
rience in engineering protease activatable probes, we 
have  identified  important  design  considerations  re-
quired for efficient development of PAPs and further 
imply that such conjugates can play an important role 
in theranostics. 
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